Navigation Links
Genzyme and Isis Announce Hart-Scott-Rodino Approval of Collaboration
Date:2/1/2008

CAMBRIDGE, Mass. and CARLSBAD, Calif., Feb. 1 /PRNewswire-FirstCall/ -- Genzyme Corp. (Nasdaq: GENZ) and Isis Pharmaceuticals, Inc. (Nasdaq: ISIS) today announced that they have received clearance under the Hart-Scott-Rodino Antitrust Improvements Act for their collaboration, which was announced on January 7, 2008. Based on this approval, Genzyme will pay Isis $150 million to purchase five million shares of Isis common stock for $30 per share.

Upon completion of final contracts, Genzyme will pay to Isis an additional up-front cash payment of $175 million for the exclusive licensing of mipomersen. As part of the strategic alliance, Genzyme will develop and commercialize mipomersen, a breakthrough, potential blockbuster lipid-lowering treatment for high risk cardiovascular patients that utilizes Isis' novel antisense technology. Isis will also be eligible to receive milestone and profit sharing payments for mipomersen, which is currently in phase 3 development. In addition, Genzyme will have preferred access to future drugs developed by Isis for CNS and certain rare diseases.

ABOUT GENZYME

One of the world's leading biotechnology companies, Genzyme is dedicated to making a major positive impact on the lives of people with serious diseases. Since 1981, the company has grown from a small start-up to a diversified enterprise with more than 10,000 employees in locations spanning the globe and 2006 revenues of $3.2 billion. In 2007, Genzyme was chosen to receive the National Medal of Technology, the high
'/>"/>

SOURCE Genzyme Corp.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related biology technology :

1. Genzyme and Isis Announce Strategic Alliance Including Exclusive Worldwide License of Mipomersen
2. BioMarin and Genzyme Restructure Aldurazyme 50/50 Joint Venture
3. Genzyme Receives European CE Mark for Single-Treatment Synvisc-One(TM)
4. Genzyme Announces FDA Approval of Thyrogen(R) for Use in Thyroid Cancer Ablation
5. Genzyme Study of Myozyme(R) for Late-Onset Pompe Patients Meets Co-Primary Efficacy Endpoints
6. Genzyme and Sunway to Collaborate on Gene Therapy Program in China
7. BioVex Appoints Genzyme Executive, Jan van Heek, as Chairman of the Board of Directors
8. Genzyme Launches Cholestagel(R) in Europe
9. FDA Approves Genzymes Renvela(TM) for Dialysis Patients
10. Genzyme to Participate in FDA Advisory Committee Meeting on the Use of Phosphate Binders in Chronic Kidney Disease
11. Genzyme Recognized by Scientists as a Top Employer
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/24/2014)... scientists are making progress in devising suitable means ... relies on quantum dotsa kind of artificial atom, ... new study demonstrates that changing the coupling of ... impulses can help better control them. This has ... quantum information units, which would produce faster quantum ...
(Date:7/24/2014)... Your cell phone may stay ... battery storage capacity. , New research indicates that ... created at Lawrence Livermore National Laboratory ... carbon components will perform as electrodes. , The ... need for higher-performance batteries. Several key characteristics of ...
(Date:7/24/2014)... , July 24, 2014  Neogen Corporation (Nasdaq: ... future forecasts of its potential revenue from new rodenticide ... to investors and analysts on July 22, 2014, Neogen,s ... analysts regarding this research. "It was my ... about the potential of a new type of rodenticide, ...
(Date:7/24/2014)... BETHESDA, Md. , July 24, 2014  Spherix ... to the fostering and monetization of intellectual property, today ... for the period ending June 30, 2014 on Monday, ... conference call at 10 a.m. ET on Monday, August ... to be led by the company,s CEO, Anthony ...
Breaking Biology Technology:Getting More Life out of Lithium-ion Batteries 2Neogen comments on SenesTech 2Spherix Schedules Shareholder Update Call 2
... ON, July 3 /PRNewswire-FirstCall/ - Vasogen Inc.,(NASDAQ: VSGN ... additional,restructuring plans to further reduce its cash burn ... strategic alternatives that may,include potential acquisitions and mergers. ... completed an extensive review of its VP,series of ...
... NEW BRUNSWICK, N.J., July 3 Senesco,Technologies, Inc. ... announced today,that it has contracted with Polyplus-transfection (Illkirch, ... of Senesco,s,combination therapy of siRNA against Factor 5A ... Senesco has previously reported positive preclinical in vivo ...
... 3 Antigen Discovery Inc. ("ADI",formerly ImmPORT Therapeutics ... advanced genomics and proteomics tools,announced today that the ... the,National Institute of Allergy and Infectious Diseases (NIAID) ... $3 million grant will,fund efforts to further develop ...
Cached Biology Technology:Vasogen Provides Corporate Update 2Senesco Signs a Supply Agreement for Polyplus-transfection's Delivery System 2Senesco Signs a Supply Agreement for Polyplus-transfection's Delivery System 3Senesco Signs a Supply Agreement for Polyplus-transfection's Delivery System 4Antigen Discovery Inc. Awarded a SBIR Phase II Grant to Commercialize Novel Antigens for Serodiagnostic Products and Vaccine Development 2
(Date:7/24/2014)... native animal species for food or commercial food sale, ... in the decline of many species of primates and ... more than half of the species being consumed are ... surveying not only the meat made available for sale ... forest by hunters and brought to villages for consumption, ...
(Date:7/24/2014)... a smog-free Los Angeles, where electric cars ply silent ... on heat from beneath the earth, from howling winds ... Stanford study finds that it is technically and economically ... powered by clean, renewable energy. Published in Energy ... inexpensive and reliable energy supply in California that could ...
(Date:7/24/2014)... multi-institutional team of researchers has developed a new nanoscale ... noninvasive method for assessing the function and properties of ... better diagnosis and treatment of gut diseases. ... bowel syndrome and inflammatory bowel disease all occur in ... in patients with diseases such as diabetes and Parkinson,s. ...
Breaking Biology News(10 mins):Stanford study shows how to power California with wind, water and sun 2Stanford study shows how to power California with wind, water and sun 3Stanford study shows how to power California with wind, water and sun 4New imaging agent provides better picture of the gut 2
... low levels of particulate air pollution may increase the ... suggest current exposure standards could be insufficient to protect ... public is exposed to ambient air pollution at the ... suggesting a potentially large public health impact," said Lynda ...
... People with highly developed emotional sensibilities are better at ... the Journal of Consumer Research. "Consumers who understand ... such as health decisions and product choices," explain the ... Childers (University of Kentucky). "A person can know a ...
... Medical Research, led by Jos Luis Milln, Ph.D., have ... replacement therapy to prevent hypophosphatasia (HPP), a primary skeletal ... foundation for future clinical trials for HPP patients. ... that most commonly results from a lack of vitamin ...
Cached Biology News:Even low levels of air pollution may pose stroke risk 2Potential therapy discovered for hypophosphatasia, a congenital form of rickets 2
Request Info...
... Quickly, effectively seals labware. Waterproof, moisture-proof ... anhydrous materials. Can be folded repeatedly ... rupturing. Stretched lengthwise at 21C (70F), ... when tension is removed, film only ...
...
Normal human AB serum, pooled...
Biology Products: